Zu den Inhalten springen
Marien Hospital Herne
St. Elisabeth Gruppe
HomeHome
Klinik für Urologie

PROOF 302

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

© Marien Hospital Herne | Impressum | . Datenschutz | . Datenschutz­einstellungen anpassen.